Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.

导出 OA

翻译打印收藏纠错

第一作者： Sofia,Sagredou

第一单位： Laboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece.

作者： Sofia,Sagredou ^[1] ; Panagiotis,Dalezis ^[1] ; Eirini,Papadopoulou ^[2] ; Maria,Voura ^[3] ; Maria V,Deligiorgi ^[1] ; Michail,Nikolaou ^[1] ; Mihalis I,Panayiotidis ^[4] ; George,Nasioulas ^[5] ; Vasiliki,Sarli ^[6] ; Dimitrios T,Trafalis ^[2]

作者单位： Laboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece. ^[1] Genekor Medical, Spaton 52, Ave., 15344 Athens, Greece. ^[2] Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece. ^[3] 1st Oncology Department, "Saint Savas" Anticancer-Oncology Hospital, 11522 Athens, Greece. ^[4] Department of Electron Microscopy & Molecular Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia 2371, Cyprus. ^[5] The Cyprus School of Molecular Medicine, P.O. Box 23462, Nicosia 1683, Cyprus. ^[6]

关键词 MMR impairment PD-L1 upregulation cancer immunogenic markers thiadiazole derivative tumor mutation burden

DOI 10.3390/pharmaceutics13060885

PMID 34203761

发布时间 2021-07-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交